CannLabs, Inc. (CANL)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
CannLabs, Inc. (CANL) trades at $0.00 with AI Score 57/100 (Grade B). CannLabs, Inc. operates as a specialized cannabis testing laboratory in the United States, offering a comprehensive suite of analytical services to ensure product quality and safety. Market cap: $93,317, Sector: Healthcare.
Price live · AI analysis from Jun 14, 2026Analyst Coverage for CANL: CANL does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CANL against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
CANL: 2/4 perspectives are bullish. Dominant signal: Seth Klarman bullish.
How is this calculated? →CannLabs, Inc. (CANL) Healthcare & Pipeline Overview
CannLabs, Inc. is a U.S.-based cannabis testing laboratory providing essential analytical services, including potency, residual solvent, and microbiological testing, alongside data analytics and education. The company supports quality assurance and regulatory compliance within the rapidly evolving cannabis sector, headquartered in Denver, Colorado.
What Is the Investment Thesis for CANL?
CannLabs, Inc. operates within the critical and expanding cannabis testing sector, providing essential quality assurance and regulatory compliance services across the United States. The company's comprehensive testing portfolio, encompassing potency, residual solvent, microbiological, and heavy metals analysis, positions it as a key infrastructure provider for cultivators and processors. With a reported profit margin of 19.8% and a gross margin of 47.0%, CannLabs demonstrates operational efficiency in its specialized service offerings. The ongoing expansion of cannabis legalization across more U.S. states presents a significant growth catalyst, driving increased demand for mandatory product testing. The company's additional services, including data/analytics and consulting, offer diversified revenue streams and strengthen client relationships by providing value beyond basic testing. However, the company's 93K market capitalization, P/E ratio of 0.1, and high Beta of 5.59 suggest a highly speculative investment profile, potentially reflecting early-stage development or limited public trading activity. The 'OTC Other' classification and 'Unknown' disclosure status introduce significant transparency and liquidity risks that warrant thorough due diligence.
Based on FMP financials and quantitative analysis
CANL Key Highlights
- The company maintains a strong gross margin of 47.0%, indicating efficient management of its service delivery costs.
- CannLabs, Inc. reported a profit margin of 19.8%, reflecting its ability to convert revenue into net income within its specialized market.
- With a P/E ratio of 0.1, the company's valuation metrics suggest a potentially low earnings multiple relative to its profitability.
- The company exhibits a high Beta of 5.59, indicating significantly higher volatility compared to the broader market.
- CannLabs, Inc. operates with a market capitalization of 93K, suggesting a micro-cap or thinly traded status.
Who Are CANL's Competitors?
CANL is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ALVO Alvotech | $3.51 | -2.77% | $1.19B | 69 |
| AERI Aerie Pharmaceuticals, Inc. | $15.25 | +0.00% | 68 | |
| KIN Kindred Biosciences, Inc. | $9.25 | +0.11% | 68 | |
| CNVCF BioHarvest Sciences Inc. | $6.30 | +0.00% | $109.16M | 66 |
| ALIM Alimera Sciences, Inc. | $5.54 | -0.18% | $301.29M | 60 |
| EGRX Eagle Pharmaceuticals, Inc. | $0.67 | +0.00% | $8.82M | 60 |
| ADMP Adamis Pharmaceuticals Corporation | $0.78 | +0.85% | $7.25M | 61 |
| DCPH Deciphera Pharmaceuticals | $25.59 | +0.08% | $2.21B | 61 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CANL's Key Strengths?
- Comprehensive range of specialized cannabis testing laboratory services.
- Strong gross margin of 47.0% and profit margin of 19.8% indicate operational efficiency.
- Headquartered in Denver, Colorado, a mature cannabis market, potentially providing a strategic base.
- Offers value-added services like data/analytics, consulting, and education beyond core testing.
What Are CANL's Weaknesses?
- Market capitalization of 93K suggests very limited market presence or liquidity.
- Trades on the 'OTC Other' tier with 'Unknown' disclosure status, indicating significant transparency challenges.
- High Beta of 5.59 points to extreme stock price volatility.
- Reliance on the evolving and fragmented regulatory landscape of the cannabis industry.
What Could Drive CANL Stock Higher?
- Further state-level cannabis legalization in the U.S. could significantly expand the addressable market for testing services, driving increased demand for CannLabs' offerings.
- The increasing emphasis on consumer safety and product quality within the cannabis industry continues to drive the need for rigorous, third-party laboratory testing.
- Any future improvements in the company's disclosure status or financial reporting could enhance investor confidence and potentially improve market visibility.
- Expansion of CannLabs' specialized testing capabilities into new, high-demand areas like advanced genetic profiling or specific therapeutic compound analysis.
What Are the Key Risks for CANL?
- The 'Unknown' disclosure status poses a significant risk to investors due to a complete lack of transparent financial and operational information.
- Trading on the 'OTC Other' tier with a 93K market cap implies extremely low liquidity, making it difficult to buy or sell shares efficiently and potentially leading to significant price volatility.
- Rapid and unpredictable changes in cannabis regulations across different U.S. states could necessitate costly adaptations to testing protocols and compliance frameworks.
- Intense competition within the cannabis testing market could pressure pricing and market share, impacting profitability and growth prospects.
- The high Beta of 5.59 indicates extreme sensitivity to market fluctuations, suggesting that the stock price could experience substantial declines during broader market downturns.
What Are the Growth Opportunities for CANL?
- **Expansion of Cannabis Legalization:** The ongoing trend of cannabis legalization across additional U.S. states presents a substantial growth opportunity for CannLabs, Inc. As more states establish regulated cannabis markets, the demand for mandatory product testing for potency, purity, and safety will inevitably increase. Each new state market represents a potential expansion territory for CannLabs' services, allowing the company to leverage its existing expertise and infrastructure. This geographic expansion could significantly broaden the company's client base and revenue streams over the next 5-10 years, contingent on navigating diverse state-specific regulatory frameworks.
- **Increasing Demand for Product Safety and Quality Assurance:** Consumer and regulatory bodies are placing a heightened emphasis on the safety and quality of cannabis products. This trend drives a continuous need for sophisticated testing services, including advanced contaminant screening for pesticides, heavy metals, and microbiological agents. CannLabs, Inc.'s comprehensive testing portfolio directly addresses this demand. As the market matures, companies that can demonstrate consistent quality and safety through rigorous testing will gain a competitive edge, thereby increasing the value and necessity of CannLabs' offerings. This demand is expected to grow steadily over the next decade.
- **Diversification into Advanced Testing Methodologies:** CannLabs, Inc. already offers advanced services like gene expression testing and genotyping/phenotyping. Expanding research and development into new, cutting-edge analytical methodologies, such as cannabinoid and terpene profiling for specific therapeutic effects or personalized medicine applications, could unlock new market segments. Investing in proprietary testing methods or advanced data analytics tools for strain characterization could differentiate CannLabs and attract clients seeking deeper scientific insights. This area represents a mid-to-long term growth avenue, potentially yielding returns within 3-7 years.
- **Data and Analytics Services for Market Insights:** Beyond raw testing results, the data generated by CannLabs' extensive testing operations holds significant value. Developing and offering enhanced data analytics and market intelligence services can provide clients with actionable insights into product trends, consumer preferences, and regulatory compliance benchmarks. This could evolve into a subscription-based service model, providing recurring revenue. By transforming raw data into strategic information, CannLabs can become a more integral partner to its clients, offering a higher-value service that extends beyond basic lab work. This opportunity could mature within the next 2-5 years.
- **Education and Consulting Services Expansion:** CannLabs, Inc. currently offers education and consulting services. Expanding these offerings to include accredited training programs, certification courses, or specialized consulting for new market entrants could create additional revenue streams and strengthen the company's industry presence. As the cannabis industry professionalizes, there will be a growing need for expert guidance on best practices, regulatory compliance, and quality control. Positioning itself as a knowledge leader through robust educational platforms could enhance brand reputation and client loyalty over the next 3-5 years.
What Opportunities Does CANL Have?
- Continued expansion of cannabis legalization across more U.S. states, increasing demand for testing.
- Growing consumer and regulatory emphasis on product safety and quality driving demand for rigorous analysis.
- Potential to expand data and analytics services into a higher-margin, recurring revenue stream.
- Diversification into new, advanced testing methodologies or specialized research services.
What Threats Does CANL Face?
- Intense competition from other specialized cannabis testing labs and larger analytical service providers.
- Rapid changes in cannabis regulations across states, requiring continuous adaptation and investment.
- Technological advancements in testing equipment or methodologies that could render current processes obsolete.
- Potential for consolidation in the cannabis industry, leading to fewer, larger clients with greater bargaining power.
What Are CANL's Competitive Advantages?
- Comprehensive suite of testing services covering a broad spectrum of analytical needs, from basic potency to advanced genetic analysis.
- Specialized expertise in navigating complex and evolving state-specific cannabis regulations.
- Established laboratory infrastructure and technical capabilities in a highly specialized field.
- Potential for proprietary methodologies or data insights from extensive testing operations.
- Reputation as a trusted third-party validator, crucial for building consumer confidence in a regulated industry.
What Does CANL Do?
CannLabs, Inc. is a dedicated provider of cannabis testing laboratory services across the United States, headquartered in Denver, Colorado. The company plays a critical role in the burgeoning cannabis industry by ensuring product safety, quality, and compliance with various state-level regulations. Its comprehensive suite of testing services addresses a wide spectrum of analytical needs for cannabis cultivators, processors, and dispensaries. Key testing offerings include potency testing, which quantifies cannabinoid content such as THC and CBD; residual solvent analysis, vital for ensuring products are free from harmful processing chemicals; and microbiological testing to detect contaminants like mold, yeast, and bacteria. Additionally, CannLabs, Inc. performs pesticide testing, heavy metals testing, and nutrient analysis, all crucial for consumer safety and product integrity. The company also delves into more specialized areas such as terpenes analysis, which identifies compounds responsible for aroma and flavor profiles, and shelf-life/stability studies to determine product longevity. Furthermore, CannLabs, Inc. offers advanced genetic services, including gene expression testing and genotyping/phenotyping testing, providing deeper insights into cannabis strains. Beyond its core laboratory services, CannLabs, Inc. extends its value proposition through data and analytics offerings, providing crucial market insights and trend analysis to its clients. The company also engages in consulting services, leveraging its expertise to guide businesses through regulatory complexities and operational best practices. Complementing these services, CannLabs, Inc. provides education services, aiming to elevate industry standards and knowledge among stakeholders. With 37 employees, CannLabs, Inc. positions itself as a foundational support system for the cannabis industry, contributing to its professionalization and consumer trust.
What Products and Services Does CANL Offer?
- Provides potency testing to quantify cannabinoid content (e.g., THC, CBD) in cannabis products.
- Conducts residual solvent analysis to ensure products are free from harmful processing chemicals.
- Performs microbiological testing to detect contaminants like mold, yeast, and bacteria.
- Offers pesticide testing and heavy metals testing for consumer safety and regulatory compliance.
- Provides nutrient analysis and terpenes analysis to understand product composition and characteristics.
- Undertakes shelf-life and stability studies to determine product longevity and quality over time.
- Engages in gene expression testing and genotyping/phenotyping for advanced strain analysis.
- Offers data/analytics, consulting, and education services to support the cannabis industry.
How Does CANL Make Money?
- Generates revenue primarily through fees for a wide range of analytical cannabis testing services.
- Monetizes its expertise by offering data and analytics services to clients for market insights.
- Provides consulting services, advising cannabis businesses on regulatory compliance and operational best practices.
- Offers education services, potentially through workshops or training programs, to industry professionals.
What Industry Does CANL Operate In?
CannLabs, Inc. is positioned within the Drug Manufacturers - Specialty & Generic industry, specifically focusing on the analytical testing segment of the rapidly expanding cannabis market. This niche sector is characterized by stringent and evolving regulatory requirements across various U.S. states where cannabis is legal. The demand for cannabis testing services is directly tied to the growth of both medical and recreational cannabis markets, driven by increasing consumer awareness of product safety and quality. The competitive landscape includes other specialized cannabis testing laboratories, as well as broader analytical service providers that may have expanded into cannabis. Key market trends include the standardization of testing protocols, advancements in analytical technologies, and the increasing need for robust data to inform product development and regulatory compliance. CannLabs' comprehensive service offering, from potency to genetic testing, positions it to address diverse client needs within this dynamic and highly regulated environment.
Who Are CANL's Key Customers?
- Cannabis cultivators and growers requiring testing for harvest quality and compliance.
- Cannabis processors and manufacturers needing analysis for extracts, edibles, and other derivative products.
- Dispensaries and retailers seeking third-party verification of product quality and safety.
- Researchers and product developers requiring specialized genetic and stability studies.
- New market entrants and established businesses seeking consulting and educational support.
Company Profile
CannLabs, Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Denver, US. The company is led by CEO Mark C. Mirken. CANL has traded publicly since 2014.
CannLabs, Inc. (CANL) Valuation Context
Valued at 93K, CANL is classified as a micro-cap stock. Relative to its peer group, CANL's quantitative score of 57/100 is roughly in line with the peer average of 66/100.
ROE 38%Key Financial Metrics
Return on equity for CannLabs, Inc. stands at 37.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 26.8%, showing how much profit it generates from its asset base. CANL trades at a trailing price-to-earnings ratio of 0.09, below the Healthcare sector average of ~23x. A current ratio of 23.93 indicates the company holds enough short-term assets to cover its near-term obligations.
F-Score 5/9Financial Health
CannLabs, Inc.'s Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 4.26 places it in the safe zone, indicating low near-term bankruptcy risk.
CANL Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- CannLabs seems to be generating some buzz in online trading circles lately. Could be a sign of increased interest and potential momentum.
- There's been talk about potential new partnerships or expansions for CannLabs. If true, that could be a catalyst for growth.
- Some insiders may be seeing value, as there's been chatter about recent insider buying activity, which could signal confidence.
- CannLabs is operating in a sector with a lot of long-term potential. If they can establish a strong foothold, they could be well-positioned.
Bear Case
- The overall sentiment seems cautious, with many traders expressing concerns about CannLabs' long-term viability.
- CannLabs faces intense competition. They'll need to differentiate themselves to stand out and maintain market share.
- There's been some negative press surrounding CannLabs recently, which could be impacting investor confidence and market perception.
- The company's sector is subject to evolving regulations. Uncertainty in the legal landscape could pose challenges and risks.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
CANL Latest News
No recent news available for CANL.
CANL Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CANL.
Price Targets
Wall Street price target analysis for CANL.
CANL MoonshotScore
What does this score mean?
The MoonshotScore rates CANL's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Mark C. Mirken
Chief Executive Officer
Unknown. Information regarding Mark C. Mirken's specific career history, educational background, previous roles, and credentials prior to his current position at CannLabs, Inc. is not provided in the available source data.
Track Record: Unknown. Specific achievements, strategic decisions, or company milestones directly attributable to Mark C. Mirken's leadership at CannLabs, Inc. are not detailed in the provided information.
CANL OTC Market Information
The 'OTC Other' tier, where CannLabs, Inc. trades, represents the lowest and most speculative segment of the over-the-counter market. Unlike companies listed on major exchanges like NYSE or NASDAQ, which adhere to strict listing requirements regarding financial standards, corporate governance, and disclosure, companies on 'OTC Other' have minimal or no reporting obligations to the SEC. This tier is typically for companies that are distressed, defunct, or have not provided current information to OTC Markets Group. It contrasts sharply with OTCQX and OTCQB, which have higher financial and disclosure standards, aiming for greater transparency and investor confidence. Investing in 'OTC Other' stocks carries significantly elevated risks due to the lack of readily available information and regulatory oversight.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- **Lack of Transparency:** The 'Unknown' disclosure status means investors have no access to current financial statements, operational reports, or material news, making informed decision-making nearly impossible.
- **Extremely Low Liquidity:** Trading on the 'OTC Other' tier with a 93K market cap implies very few buyers and sellers, leading to wide bid-ask spreads and significant difficulty in trading shares.
- **High Volatility:** A Beta of 5.59 indicates extreme price swings, which, combined with low liquidity, can result in rapid and substantial capital losses.
- **Limited Regulatory Oversight:** Companies on 'OTC Other' are subject to minimal regulatory scrutiny compared to exchange-listed or even higher-tier OTC stocks, increasing the risk of fraud or mismanagement.
- **Difficulty in Valuation:** Without reliable financial data and market activity, accurately valuing the company's shares is exceptionally challenging, leading to speculative pricing.
- Verify any available information directly from the company or independent third-party sources, if possible, given the 'Unknown' disclosure status.
- Assess the current operational status and market presence of CannLabs, Inc. beyond the provided business description.
- Investigate any historical financial filings or public records that might exist, even if not current.
- Understand the specific regulatory environment in which the company operates and its compliance track record.
- Evaluate the competitive landscape and CannLabs' actual market share or differentiation, if any data can be found.
- Research the background and track record of Mark C. Mirken and other key management personnel, if information is available.
- Consider the potential for delisting or further market tier degradation given the current status.
- The company is based in Denver, Colorado, a significant hub for the cannabis industry, which could indicate a strategic location.
- It operates in a legitimate and growing sector (cannabis testing), providing essential services for product quality and safety.
- The company has a stated number of employees (37), suggesting an active operational presence.
- The comprehensive list of testing services indicates a specialized and technical business model.
CANL Healthcare Stock FAQ
What does CannLabs, Inc. do?
CannLabs, Inc. is a specialized cannabis testing laboratory based in Denver, Colorado, providing a comprehensive range of analytical services across the United States. Its core business involves ensuring the safety, quality, and regulatory compliance of cannabis products through various testing methodologies. This includes potency testing for cannabinoid content, residual solvent analysis, microbiological testing for contaminants, pesticide and heavy metals screening, and nutrient analysis. Additionally, the company offers more advanced services such as terpenes analysis, shelf-life studies, and genetic testing (gene expression and genotyping/phenotyping). Beyond laboratory analysis, CannLabs, Inc. extends its value proposition by offering data and analytics services for market insights, consulting for regulatory guidance, and educational programs for industry stakeholders, positioning itself as a multifaceted support system for the cannabis sector.
How does CannLabs, Inc. navigate regulatory approval processes in the cannabis sector?
CannLabs, Inc. operates within a highly fragmented and evolving regulatory landscape, as cannabis legality and testing requirements vary significantly from state to state in the U.S. The company's navigation of these processes involves adhering to each state's specific mandates for cannabis product testing, which can include different thresholds for contaminants, required cannabinoid profiles, and reporting standards. While the cannabis industry does not typically involve FDA or EMA regulatory approval processes in the same way as traditional pharmaceuticals, CannLabs' compliance strategy centers on maintaining accreditations pertinent to cannabis testing, such as ISO/IEC 17025, and staying abreast of legislative changes. The company's consulting services likely assist clients in understanding and meeting these diverse regulatory obligations, though specific details on CannLabs' own regulatory track record or pending approvals are not provided in the available data.
What revenue streams does CannLabs, Inc. have in healthcare?
CannLabs, Inc.'s primary revenue streams within the healthcare sector are derived from its specialized cannabis testing laboratory services. These services are crucial for ensuring the safety and quality of cannabis products, which are increasingly used for medical purposes. Revenue is generated from fees charged for a wide array of tests, including potency analysis, residual solvent detection, microbiological screening, pesticide and heavy metals testing, and genetic profiling. These services are essential for cannabis cultivators, processors, and dispensaries to meet regulatory compliance and consumer health standards. Beyond direct testing, the company also generates revenue from data and analytics services, providing valuable insights to clients, and from consulting services, where its expertise guides businesses through complex regulatory and operational challenges. Additionally, education services contribute to revenue by offering training and knowledge dissemination within the professional cannabis community, all supporting the broader healthcare ecosystem where cannabis products are utilized.
What are the main risks for CANL?
The primary risks for CannLabs, Inc. are multifaceted, stemming significantly from its market classification and the nature of the cannabis industry. A major concern is the 'Unknown' disclosure status, which means there is no public access to current financial statements or operational updates, making informed investment decisions exceptionally difficult. This lack of transparency is compounded by its trading on the 'OTC Other' tier with a 93K market capitalization, indicating extremely low liquidity. This illiquidity can lead to wide bid-ask spreads and significant challenges in buying or selling shares without impacting the price. Furthermore, the company's high Beta of 5.59 suggests extreme stock price volatility, exposing investors to substantial capital loss risk. Operationally, the cannabis industry's fragmented and rapidly changing regulatory environment across U.S. states presents ongoing compliance challenges and potential for costly adaptations. Intense competition from other testing laboratories also poses a threat to market share and pricing power.
What are the key factors to evaluate for CANL?
CannLabs, Inc. (CANL) holds an AI score of 57/100 (moderate). P/E: 0.1x vs the S&P 500's ~20-25x. Not financial advice.
How frequently does CANL data refresh on this page?
CANL prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven CANL's recent stock price performance?
CannLabs, Inc. (CANL) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Comprehensive range of specialized cannabis testing laboratory services. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CANL overvalued or undervalued right now?
CannLabs, Inc. (CANL) trades at 0.1x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information on CEO background, track record, and tenure is not available in the provided source data and has been marked as 'Unknown' or 'null'.
- Competitor information (FMP PEER TICKERS) was not provided, resulting in an empty array for the 'competitors' field.
- Growth opportunities and SWOT analysis were inferred based on the company's business description and general industry knowledge, as specific details were not provided in the source data.
- The 'Unknown' disclosure status for OTC analysis significantly limits the depth of financial and operational assessment.